Merck, Eisai's Two Phase 3 Trials Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) In Certain Types Of Metastatic Non-small Cell Lung Cancer Did Not Meet Its Dual Primary Endpoints Of Overall Survival And Progression-free Survival
Portfolio Pulse from Benzinga Newsdesk
Merck and Eisai's two Phase 3 trials evaluating Keytruda plus Lenvima in certain types of metastatic non-small cell lung cancer did not meet its dual primary endpoints of overall survival and progression-free survival.
September 22, 2023 | 10:49 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eisai's Phase 3 trials for Keytruda and Lenvima did not meet primary endpoints, which could negatively impact the company's stock.
The failure of the Phase 3 trials means that Eisai's potential revenue from these drugs could be significantly reduced. This could lead to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Merck's Phase 3 trials for Keytruda and Lenvima did not meet primary endpoints, which could negatively impact the company's stock.
The failure of the Phase 3 trials means that Merck's potential revenue from these drugs could be significantly reduced. This could lead to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100